Evidence map›Paper›PMID 35683129›Full record

ArticleMaterials (Basel, Switzerland)2022

Fluorescently Labeled Gadolinium Ferrate/Trigadolinium Pentairon(III) Oxide Nanoparticles: Synthesis, Characterization, In Vivo Biodistribution, and Application for Visualization of Myocardial Ischemia-Reperfusion Injury.

Dmitry V Korolev, Galina A Shulmeyster, Maria S Istomina, Natalia V Evreinova, Ilia V Aleksandrov, Aleksandr S Krasichkov, Viktor N Postnov, Michael M Galagudza

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dmitry V KorolevInstitute of Experimental Medicine, Almazov National Medical Research Centre, Saint-Petersburg 197341, Russia.
Galina A ShulmeysterInstitute of Experimental Medicine, Almazov National Medical Research Centre, Saint-Petersburg 197341, Russia.
Maria S IstominaInstitute of Experimental Medicine, Almazov National Medical Research Centre, Saint-Petersburg 197341, Russia.
Natalia V EvreinovaInstitute of Experimental Medicine, Almazov National Medical Research Centre, Saint-Petersburg 197341, Russia.
Ilia V AleksandrovInstitute of Experimental Medicine, Almazov National Medical Research Centre, Saint-Petersburg 197341, Russia.ORCID 0000-0001-8286-8070
Aleksandr S KrasichkovDepartment of Radio Engineering Systems, Saint-Petersburg Electrotechnical University "LETI", Saint-Petersburg 197376, Russia.
Viktor N PostnovInstitute of Experimental Medicine, Almazov National Medical Research Centre, Saint-Petersburg 197341, Russia.
Michael M GalagudzaInstitute of Experimental Medicine, Almazov National Medical Research Centre, Saint-Petersburg 197341, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various gadolinium compounds have been proposed as contrasting agents for magnetic resonance imaging (MRI). In this study, we suggested a new synthesis method of gadolinium ferrate/trigadolinium pentairon(III) oxide nanoparticles (GF/TPO NPs). The specific surface area of gadolinium ferrate (GdFeO

Indexed as

biodistributionfluorophoresgadolinium ferrateindocyanine greenmyocardial ischemia–reperfusion injurynanoparticlestrigadolinium pentairon(III) oxide

Identifiers

PMID35683129
PMCPMC9181512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.